Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Oxytocin
Well-studied neuropeptide with extensive human research on social/emotional processing. Prescription product.
Tier Amed-high risk
02· Subject
DSIP
Sleep-related peptide with human IV infusion studies showing sleep pressure effects. Mechanism uncertain.
Tier Bmed-high risk
01 · At a glance
| Decision factor | Oxytocin | DSIP | Selank |
|---|---|---|---|
| Primary fit | sexual health & libido and anxiety & mood comparisons | sleep & relaxation and anxiety & mood comparisons | cognitive & neuroprotection and sleep & relaxation comparisons |
| Evidence | Tier A | Tier B | Tier B-C |
| Risk | med-high | med-high | med-high |
| Experience level | advanced | intermediate | intermediate |
| Budget tier | mid | mid | mid |
| Administration route | intranasal, intravenous | intravenous, subcutaneous | intranasal |
02 · Use case & timing
| Decision factor | Oxytocin | DSIP | Selank |
|---|---|---|---|
| Goal fit | Sexual Health & Libido, Anxiety & Mood | Sleep & Relaxation, Anxiety & Mood | Cognitive & Neuroprotection, Sleep & Relaxation, Anxiety & Mood |
| What users compare it for | Social cognition, bonding, anxiety modulation effects in research settings. | Sleep pressure effects in some human studies; outcomes inconsistent across trials. | Anxiolytic/calm focus effects reported in limited clinical settings. |
| Onset timeline | Acute effects studied within hours post-dose; mixed efficacy across conditions. | Acute subjective effects reported after dosing; sleep architecture outcomes assessed same day/night. | Some rapid responders described in clinical abstracts, but not broad RCT-grade evidence. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Oxytocin | DSIP | Selank |
|---|---|---|---|
| Adverse effects | Generally minimal at trial doses; vulnerable populations require caution. | Limited modern safety data; moderate uncertainty. | Limited Western regulatory data; higher scrutiny warranted. |
| Contraindications | Rx product; clinical supervision required. | No established label. | No established label. |
| Interaction notes | No uniform interaction map; treat as Rx/clinical research context. | Unknown; avoid polypharmacy recommendations. | Animal diazepam interaction explored; do not translate to human guidance. |
| Regulatory status | Prescription-approved | Not approved | Not approved |
| FDA flag | No current flag noted | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | Not listed | Status unclear |
04 · Age & monitoring
| Decision factor | Oxytocin | DSIP | Selank |
|---|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Oxytocin | DSIP | Selank |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | €8.02 | €20.64 |
| Estimated monthly cost | No reliable estimate yet | €16.05 | €27.52 |
| Cost confidence | No estimate | High confidence | High confidence |
06 · Before you buy
| Decision factor | Oxytocin | DSIP | Selank |
|---|---|---|---|
| Tracked vendor listings | 1 listing | 3 listings | 3 listings |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Better as a standalone decision | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.